title: Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
abstract: Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: J
authors: J
authors: Gao
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Q
authors: Q
authors: He
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: S
authors: S
authors: Subudhi
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: A
authors: A
authors: Aparicio
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: A
authors: A
authors: Zurita-Saavedra
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: D H
authors: DH
authors: Lee
authors: Department of Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: C
authors: C
authors: Jimenez
authors: Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: M
authors: M
authors: Suarez-Almazor
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: P
authors: P
authors: Sharma
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab